Natixis Makes New $1.85 Million Investment in AtriCure, Inc. (NASDAQ:ATRC)

Natixis acquired a new stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 60,500 shares of the medical device company's stock, valued at approximately $1,849,000. Natixis owned approximately 0.12% of AtriCure as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Geode Capital Management LLC grew its holdings in shares of AtriCure by 2.9% during the third quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company's stock valued at $32,326,000 after buying an additional 32,676 shares during the last quarter. Silver Oak Securities Incorporated purchased a new stake in AtriCure in the 4th quarter worth about $220,000. JPMorgan Chase & Co. raised its position in shares of AtriCure by 43.1% in the fourth quarter. JPMorgan Chase & Co. now owns 365,183 shares of the medical device company's stock valued at $11,160,000 after purchasing an additional 110,039 shares during the period. Calamos Advisors LLC boosted its holdings in shares of AtriCure by 27.9% in the fourth quarter. Calamos Advisors LLC now owns 110,671 shares of the medical device company's stock worth $3,382,000 after acquiring an additional 24,147 shares during the period. Finally, M&T Bank Corp purchased a new position in AtriCure during the 4th quarter valued at about $208,000. Institutional investors and hedge funds own 99.11% of the company's stock.

Insider Buying and Selling

In other AtriCure news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the sale, the director now directly owns 17,828 shares of the company's stock, valued at $679,603.36. The trade was a 25.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.20% of the stock is currently owned by insiders.

AtriCure Stock Performance

Shares of NASDAQ:ATRC opened at $31.97 on Wednesday. AtriCure, Inc. has a 12 month low of $18.94 and a 12 month high of $43.11. The firm's 50-day moving average is $34.73 and its 200 day moving average is $34.48. The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of -33.65 and a beta of 1.65. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13.

Analyst Ratings Changes

ATRC has been the topic of a number of research analyst reports. Needham & Company LLC restated a "buy" rating and issued a $51.00 target price on shares of AtriCure in a research note on Thursday, March 27th. BTIG Research reiterated a "buy" rating on shares of AtriCure in a report on Thursday, March 27th. Stifel Nicolaus upped their price target on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Canaccord Genuity Group reduced their target price on AtriCure from $66.00 to $52.00 and set a "buy" rating on the stock in a research note on Friday, March 28th. Finally, Piper Sandler raised their price objective on shares of AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $49.44.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.